John Monte Knobeloch is a notable inventor based in Indianapolis, IN (US). He has made significant contributions to the field of pharmaceutical research, particularly in the development of compounds that target specific diseases. With a total of 2 patents, his work has the potential to impact the treatment of various cell proliferative diseases.

Latest Patents

Knobeloch's latest patents include innovative compounds that serve as protein kinase inhibitors. The first patent presents a compound of formula (I) or a pharmaceutically acceptable salt thereof, which is useful in the treatment of cell proliferative diseases. His second patent focuses on imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors, providing compounds that inhibit VEGF-R2 of the formula (I) and methods for utilizing these compounds.

Career Highlights

John Monte Knobeloch is currently employed at Eli Lilly and Company, a leading pharmaceutical company known for its commitment to innovation and research. His work at Eli Lilly has allowed him to explore and develop groundbreaking treatments that address critical health issues.

Collaborations

Throughout his career, Knobeloch has collaborated with esteemed colleagues, including David Andrew Coates and Lawrence Mark Gelbert. These collaborations have fostered an environment of innovation and have contributed to the advancement of pharmaceutical research.

Conclusion

John Monte Knobeloch's contributions to the field of pharmaceutical research through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for new treatments that can significantly improve patient outcomes.

Profile summary based on public USPTO records.